The Dual Antiplatelet Therapy Study (DAPT Study)

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborators:

Abbott

Boston Scientific Corporation

Bristol-Myers Squibb

Sanofi-Synthelabo

Cordis Corporation

Eli Lilly and Company

Daiichi Sankyo Inc.

Medtronic

Information provided by:

Harvard Clinical Research Institute

ClinicalTrials.gov Identifier:

NCT00977938

First received: September 14, 2009

Last updated: July 22, 2011

Last verified: July 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	December 2013 (Final data collection date for primary outcome measure)

No publications provided by Harvard Clinical Research Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010 Dec;160(6):1035-41, 1041.e1.

To Top